In 33 of 44 countries surveyed, the incidence of prostate cancer was stabilized over the last five years for which data was available – and in seven countries, the report found.
In 33 out of 44 countries surveyed, the incidence of prostate cancer was stabilized in the last five years for which data was available – and in seven countries it was down, the report found.
Death rates from prostate cancer ̵
In 33 out of 44 countries surveyed, the incidence of prostate cancer has stabilized in the last five years for which data was available – and in seven countries it was down, the report found.
Only four of the countries surveyed, including Bulgaria, experienced an increased incidence of prostate cancer, it said.
"Over the past five years, with investigated data, the incidence of prostate cancer and mortality is declining or stabilizing in most parts of the world," says author MaryBeth Freeman.
Prostate cancer deaths were down in 14 countries investigated and stable in 54 others. Only three countries experienced an increase in prostate cancer deaths according to the study results presented Tuesday at a conference in Atlanta.
The United States had the largest decrease in prostate cancer attributed to Freeman by a decrease in the use of a controversial diagnostic test that identified for many non-hazardous tumors.
The incidence of prostate cancer increased in the United States in the 1980s and early 1990s, as PSA or Prostate-Specific Antigen blood sample was widely available.  The test is inaccurate and gives too many false positives. It identifies higher than normal levels of PSA, a protein produced by the prostate, which may be indicative of cancer, but is often a symptom of other diseases.
Moreover, some prostate cancer is not aggressive and does not grow enough to pose a risk.
A false positive, on the other hand, can have harmful consequences for the patient: anxiety, complications associated with biopsies or treatment against cancer.
In 2012, the United States Preventive Services Task Force conducted an expert panel assessing the effectiveness of preventive clinical services recommended for use by the PSA test.
In 2018, the recommendation to say that taking the test should be an "individual" decision for men 55 to 69. At 70 and then it was against its use.